This valuable study investigates the role of HIF1a signaling in epicardial activation and neonatal heart regeneration in mice. Using a combination of genetic and pharmacological approaches, the ...

As Europe’s pharmaceutical sector strengthens its focus on specialty intermediates, terephthalic aldehyde has become indispensable for researchers and manufacturers pursuing synthetic versatility, ...

Two clinical trials of Merck’s pulmonary arterial hypertension (PAH) drug Winrevair were so conclusive that the studies were halted within the last year because the efficacy of the treatment was ...

Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 5.7% in the afternoon session after the company announced positive results from its Phase 3 HYPERION trial for its drug, WINREVAIR™ ...

RAHWAY, N.J. - Merck (NYSE:MRK), a prominent player in the pharmaceutical industry with a market capitalization of $222.78 billion and an impressive gross profit margin of 77.41%, has initiated three ...

Merck & Co., Inc. (NYSE:MRK) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 30, Merck & Co., Inc. (NYSE:MRK) announced positive results from its Phase 3 HYPERION trial of ...

I believe that Merck (NYSE:MRK) is a good long-term pharmaceutical company to own and with that being said, it is because of several excellent moves it has made in the last few years. The first major ...

Tulisokibart, an investigational anti-TL1A monoclonal antibody currently in Phase 3 trials for ulcerative colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages of ...

A top health official has suggested breaking up the combination measles, mumps and rubella (MMR) vaccine. In response to President Donald Trump’s recent statement warning about pregnant women's use of ...